Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 7/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661495 | 0.82 | KDM4E (0.42) | DGAT1KMT2AHTTGRM5BACE1 | |
| Hydrochloric Acid SCHEMBL13729434 | 0.81 | KDM4E (0.41) | DGAT1KMT2AHTTGRM5BACE1 | |
| SCHEMBL29465147 | 0.81 | DGAT1 (0.35) | DGAT1KMT2AHTTGRM5BACE1 | |
| SCHEMBL1661089 | 0.81 | DGAT1 (0.35) | DGAT1KMT2AHTTPLAUGRM5 | |
| SCHEMBL10081962 | 0.81 | DGAT1 (0.35) | DGAT1KMT2AHTTGRM5BACE1 | |
| SCHEMBL4326940 | 0.80 | DPP4 (0.39) | KMT2AIDO1BACE1USP2PARP1 | |
| SCHEMBL30641925 | 0.80 | DPP4 (0.39) | KMT2AIDO1BACE1USP2PARP1 | |
| Hydrochloric Acid SCHEMBL28375765 | 0.78 | DPP4 (0.39) | KMT2AIDO1BACE1USP2PARP1 | |
| SCHEMBL321782 | 0.78 | HTT (0.42) | KMT2AHTTPLAUIDO1GRM5 | |
| SCHEMBL30423476 | 0.78 | HTT (0.42) | KMT2AHTTPLAUIDO1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| WO-2022175514-A1 | N-(PYRIDIN-2-YL)-ACETAMIDES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | WO | disclosed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | disclosed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | disclosed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | disclosed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | disclosed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | disclosed |
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1723143-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1706372-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | Merck & Co., Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| WO-2005085198-A2 | AMINO CYCLOPROPANE CARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005063690-A1 | ALPHA-HYDROXY AMIDES AS BRADYKININ ANTAGONISTS OR INVERSE AGONISTS | MERCK & CO., INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1545538-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019868-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201582-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | DGAT1 1475/4885KMT2A 2731/4885HTT 1969/4885 |
| US-20160297762-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | DGAT1 1475/4885KMT2A 2731/4885HTT 1969/4885 |
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | DGAT1 1475/4885KMT2A 2731/4885HTT 1969/4885 |
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | DGAT1 1475/4885KMT2A 2731/4885HTT 1969/4885 |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | DGAT1 2472/4885KMT2A 3164/4885HTT 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.